Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423326
Status:
RECRUITING
Last Update Posted:
2024-05-21
First Post:
2024-04-10
Brief Title:
Gemcitabine Cisplatin and Nab-Paclitaxel As Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer
Sponsor:
Emory University
Organization:
Emory University
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Borderline Resectable Pancreatic Ductal Adenocarcinoma |
| Resectable Pancreatic Adenocarcinoma |
| Stage I Pancreatic Cancer AJCC v8 |
| Stage II Pancreatic Cancer AJCC v8 |
| Stage III Pancreatic Cancer AJCC v8 |
Keywords: